WaveMan
WaveMan · Company
ACRS · Aclaris Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ACRS Aclaris Therapeutics (ACRS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001557746
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
95
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · no price filed

Aclaris Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Aclaris Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Leonard Braden Michael
SELL
2026-04-27 SECtraded 2026-04-23
300,000
$1.4M
-10.2%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 buys), the last on Aug 5, 2024.
  • +1.7% median (+8.5% mean) 90-day return after 19 previous buys.
  • The trade is 2.2% of the 13,950,000 shares held after it.
  • No other insider sold within 30 days.
  • 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Leonard Braden Michael sold about $1.4M of ACRS on Apr 23, 2026, the largest insider sale at the company on our record; 95 funds added in the latest 13F quarter.
Mehra Anand
Director
BUY
2024-11-20 SECtraded 2024-11-19
666,666
$1.5M
-12.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 93.9% of the 710,030 shares held after it.
  • No other insider bought within 30 days.
  • 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mehra Anand bought about $1.5M of ACRS on Nov 19, 2024, the largest insider purchase at the company on our record; 95 funds added in the latest 13F quarter.
Leonard Braden Michael
BUY
2024-08-05 SEC
206,025
$255.5K
+210.7%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Aug 2, 2024.
  • +1.3% median (+4.8% mean) 90-day return after 18 previous buys.
  • The trade is 1.4% of the 14,250,000 shares held after it.
  • No other insider bought within 30 days.
  • 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Leonard Braden Michael bought about $255.5K of ACRS on Aug 5, 2024; 95 funds added in the latest 13F quarter.
Leonard Braden Michael
BUY
2024-08-05 SECtraded 2024-08-02
167,544
$216.1K
+210.7%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 buys), the last on Jul 31, 2024.
  • +0.9% median (+2.7% mean) 90-day return after 17 previous buys.
  • The trade is 1.2% of the 14,043,975 shares held after it.
  • No other insider bought within 30 days.
  • 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Leonard Braden Michael bought about $216.1K of ACRS on Aug 2, 2024; 95 funds added in the latest 13F quarter.
Leonard Braden Michael
BUY
2024-07-31 SEC
100,000
$133.0K
+187.1%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 buys), the last on Jul 30, 2024.
  • +0.9% median (+1.1% mean) 90-day return after 16 previous buys.
  • The trade is 0.7% of the 13,876,421 shares held after it.
  • No other insider bought within 30 days.
  • 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Leonard Braden Michael bought about $133.0K of ACRS on Jul 31, 2024; 95 funds added in the latest 13F quarter.
73 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 68 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
95 funds bought in last quarter
more than 66% of Pharma & Biotech
Revenue
-58.2% year over year
below 82% of Pharma & Biotech
Margin
-829.6% net margin
below 83% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
18.0% of the float short (float per yahoo 2026-10-26) · 6.5 days to cover · settled 2026-09-30
more than 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ACRS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+67.7%12M
-6%+59%+124%+189%2025-102025-122026-022026-042026-062026-082026-10 2026-04-23 · Leonard Braden Michael sold $1.4M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ACRS: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
12,723,026 sh
$67.3M
BML Capital Management, LLC
11,975,000 sh
$63.3M
BlackRock, Inc.
10,037,008 sh
$53.1M
Deep Track Capital, LP
9,345,000 sh
$49.4M
Vivo Capital, LLC
6,694,637 sh
$35.4M

Congress trades in ACRS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ACRS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ACRS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$3.8M position · as of 2026-06-30
0.9%
PROFUND VP PHARMACEUTICALS
$99.8K position · as of 2026-06-30
0.9%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$135.3K position · as of 2026-07-31
0.7%
Invesco NASDAQ Future Gen 200 ETF
$122.3K position · as of 2026-05-31
0.6%
ALPS Medical Breakthroughs ETF
$565.6K position · as of 2026-05-31
0.3%
Ultra-Small Company Market Fund
$328.1K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
9
Phase 2
1 active
What changed recently
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
2026-09-30 · Completion moved 2026-08 → 2026-09-21
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2021
$6.9M
$12.1M
$4.0M
+670%
+26%
2020
$1.6M
$4.9M
$789.6K
+243%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 95 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ACRS financials

Revenue growth
-58.2%
XBRL, annual
Net margin
-829.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$8.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-921.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$62.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.09x
long-term debt only, 2021-06-30 (60 months older than the period end); equity 2026-06-30
Cash flow to debt
-5.78x
TTM operating cash flow over long-term debt only, 2021-06-30 (60 months older than the period end)
Return on equity
-59.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-41.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-55.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$549.4M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2021-06-30 (60 months older than the period end), minus cash 2026-06-30
FCF yield
-11.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$7.8M$18.7M$31.2M$29.8M
Operating income-$76.4M-$141.9M-$97.4M-$89.9M
Net income-$64.9M-$132.1M-$88.5M-$86.9M
EPS (diluted)-0.53-1.71-1.27-1.33
Operating cash flow-$47.1M-$20.1M-$78.3M-$67.6M
Cash$20.0M$24.6M$39.9M$45.3M
SEC XBRL, fiscal years, as known on 2026-10-27

ACRS Stock Sonar score 5/7 axes

Find similar shapesCompare

ACRS ranks highest on institutional and government (66th percentile) and profitability (49th), and lowest on growth (18th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
49
Inputs
  • Return on equity-59.1% · 48 pct, sector of 545
  • Return on assets-41.1% · 52 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-55.0% · 46 pct, sector of 576
Financial health
42
Inputs
  • Debt to equity0.09x · 56 pct, sector of 352
  • Cash flow to debt-5.78x · 28 pct, sector of 371
Growth
18
Inputs
  • Revenue growth, YoY-58.2% · 18 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
66
Inputs
  • Funds adding, latest quarter95 · 66 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
19
Inputs
  • Short interest, % of float+18.0% · 19 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies